Review Article
A Look into Stem Cell Therapy: Exploring the Options for Treatment of Ischemic Stroke
Table 1
Current completed phase I and II clinical trials on stem cell and ischemic stroke.
| Stem cell completed clinical trials for ischemic stroke | Authors | NCT | Stage of trial | Type of stem cells used/mode of delivery | Primary outcomes | Results |
| Kalladka et al. 2016 [9] | 01151124 | Phase I | NSCs: CTX-DP drug product/stereotactic ipsilateral putamen injection | Incidence of adverse events | No adverse events were seen NIHSS improvement ranged from 0–5 (secondary outcome) | Qiao et al. 2014 [69] | NA | Phase I | Cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells/IV | Safety and feasibility | No evidence of neurological deterioration or neurological infection | Prasad et al. 2014 | 02425670 | Phase II | BM mononuclear cells/IV | Functional ability-modifiedBarthel Index score | No significant difference between BMSC versus control in Barthel Index score | Banerjee et al. 2014 | 00535197 | Phase I | CD34+ stem cells/intra-arterial | Safety | Safe and feasible | Savitz and Sean 2014 | 00859024 | Phase I | Autologous mononuclear bone marrow cells/IV | Adverse events | No study-related adverse events |
|
|
IV: intravenous; BMSC: bone marrow stem cells; NIHSS: National Institute of Health Stroke Scale; NCT: National Clinical Trial Number.
|